^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GT201

    i
    Other names: GT201, Autologous tumor infiltrating lymphocyte injection, GT 201
    Associations

    News

    Trials
    Company:
    Grit Biotechnology
    Drug class:
    Immunostimulant, IL-15 modulator
    Related drugs:
    Associations

    News

    Trials
    12d
    Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer) (clinicaltrials.gov)
    P=N/A, N=4, Terminated, Grit Biotechnology | N=26 --> 4 | Trial completion date: Jun 2026 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Dec 2025; The study was terminated from a business perspective.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    GT201
    12d
    Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (clinicaltrials.gov)
    P1, N=1, Terminated, Grit Biotechnology | N=26 --> 1 | Trial completion date: Oct 2026 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Dec 2025; The study was terminated from a business perspective.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    GT201
    12d
    Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P=N/A, N=2, Terminated, Grit Biotechnology | N=40 --> 2 | Trial completion date: Jul 2027 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Jul 2027 --> Dec 2025; The study was terminated from a business perspective.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    GT201
    13d
    Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=2, Terminated, Grit Biotechnology | N=30 --> 2 | Trial completion date: May 2025 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Dec 2025; The study was terminated from a business perspective.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    GT201
    13d
    GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=2, Terminated, Grit Biotechnology | N=20 --> 2 | Trial completion date: Jan 2027 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Dec 2025; The study was terminated from a business perspective.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    GT201
    13d
    Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=6, Terminated, Grit Biotechnology | N=42 --> 6 | Trial completion date: May 2025 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Dec 2025; The study was terminated from a business perspective.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    GT201
    15d
    Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors (clinicaltrials.gov)
    P=N/A, N=32, Recruiting, Grit Biotechnology | N=12 --> 32
    Enrollment change
    |
    GT201
    1year
    Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (clinicaltrials.gov)
    P1, N=26, Recruiting, Grit Biotechnology
    New P1 trial
    |
    GT201
    over1year
    Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients with Advanced Lung Cancer (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Grit Biotechnology | N=16 --> 40
    Enrollment change
    |
    GT201
    over1year
    Clinical Study of GT201 in Combination with PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=12, Recruiting, Grit Biotechnology | N=32 --> 12
    Enrollment change
    |
    GT201
    over1year
    Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Grit Biotechnology | Phase classification: P1 --> P1/2 | N=26 --> 42
    Phase classification • Enrollment change
    |
    GT201
    almost2years
    Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P=N/A, N=16, Recruiting, Grit Biotechnology
    New trial • Metastases
    |
    GT201